Year |
Citation |
Score |
2006 |
Wender PA, Horan JC, Verma VA. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs. Organic Letters. 8: 5299-302. PMID 17078702 DOI: 10.1021/Ol0620904 |
0.564 |
|
2006 |
Wender PA, Horan JC. Synthesis and PKC binding of a new class of a-ring diversifiable bryostatin analogues utilizing a double asymmetric hydrogenation and cross-coupling strategy. Organic Letters. 8: 4581-4. PMID 16986955 DOI: 10.1021/Ol0618149 |
0.605 |
|
2006 |
Wender PA, Baryza JL, Hilinski MK, Horan JC, Kan C, Verma VA. Beyond Natural Products: Synthetic Analogues of Bryostatin 1 Drug Discovery Research: New Frontiers in the Post-Genomic Era. 125-162. DOI: 10.1002/9780470131862.ch6 |
0.704 |
|
2005 |
Wender PA, Clarke MO, Horan JC. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs. Organic Letters. 7: 1995-8. PMID 15876038 DOI: 10.1021/Ol0504650 |
0.69 |
|
2004 |
Wender PA, Baryza JL, Brenner SE, Clarke MO, Craske ML, Horan JC, Meyer T. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. Current Drug Discovery Technologies. 1: 1-11. PMID 16472215 DOI: 10.2174/1570163043484888 |
0.756 |
|
2003 |
Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems Pure and Applied Chemistry. 75: 143-155. DOI: 10.1351/Pac200375020143 |
0.659 |
|
2003 |
Wender PA, Baryza JL, Brenner SE, Clarke MO, Gamber GG, Horan JC, Jessop TC, Kan C, Pattabiraman K, Williams TJ. Inspirations from nature. New reactions, therapeutic leads, and drug delivery systems Pure and Applied Chemistry. 75: 143-155. |
0.612 |
|
2002 |
Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM. The practical synthesis of a novel and highly potent analogue of bryostatin. Journal of the American Chemical Society. 124: 13648-9. PMID 12431074 DOI: 10.1021/Ja027509+ |
0.667 |
|
Low-probability matches (unlikely to be authored by this person) |
2015 |
Horan JC, Kuzmich D, Liu P, DiSalvo D, Lord J, Mao C, Hopkins TD, Yu H, Harcken C, Betageri R, Hill-Drzewi M, Patenaude L, Patel M, Fletcher K, Terenzzio D, et al. Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists. Bioorganic & Medicinal Chemistry Letters. PMID 26687487 DOI: 10.1016/j.bmcl.2015.11.090 |
0.21 |
|
2014 |
Horan JC, Sanyal S, Choi Y, Hill-Drzewi M, Patnaude L, Anderson S, Fogal S, Mao C, Cook BN, Gueneva-Boucheva K, Fisher MB, Hickey E, Pack E, Bannen LC, Chan DS, et al. Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists. Bioorganic & Medicinal Chemistry Letters. 24: 4807-11. PMID 25241927 DOI: 10.1016/j.bmcl.2014.09.003 |
0.181 |
|
2022 |
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discovery. PMID 36511802 DOI: 10.1158/2159-8290.CD-22-0968 |
0.163 |
|
1984 |
Oei HH, Horan JC, Zoganas HC. Effects of thromboxane synthesis inhibition on the genesis of splanchnic ischemia-induced cardiovascular shock Federation Proceedings. 43: no. 4332. |
0.111 |
|
2012 |
Fryer RM, Muthukumarana A, Harrison PC, Nodop Mazurek S, Chen RR, Harrington KE, Dinallo RM, Horan JC, Patnaude L, Modis LK, Reinhart GA. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. Plos One. 7: e52985. PMID 23285242 DOI: 10.1371/journal.pone.0052985 |
0.094 |
|
1984 |
Horan JC. Repositioning development in a corporate reorganization. Fund Raising Management. 15: 54, 56-7. PMID 10265761 |
0.076 |
|
2002 |
Horan JC. Indigenous wealth and development: Micro-credit schemes in Tonga Asia Pacific Viewpoint. 43: 205-221. |
0.037 |
|
1953 |
HORAN JC. Morbidity experience under personal accident and health insurance. Transactions of the Association of Life Insurance Medical Directors of America. 37: 217-36. PMID 13169216 |
0.024 |
|
1957 |
HORAN JC. Noncancellable and guaranteed renewable insurance; underwriting considerations. Journal of the American Medical Association. 165: 1592-7; discussion 1. PMID 13475071 DOI: 10.1001/jama.1957.72980300033015d |
0.021 |
|
1956 |
HORAN JC. Noncancellable and guaranteed renewable insurance; underwriting considerations. Transactions of the Association of Life Insurance Medical Directors of America. 40: 191-203; discussion,. PMID 13433805 |
0.021 |
|
1982 |
Horan JC. Marketing--a factor in the development program. Journal (National Association For Hospital Development (U.S.)). 49-51. PMID 10309709 |
0.01 |
|
Hide low-probability matches. |